References
- Bodey G. P., Freireich F. J., Monto R. W., et al. Cytosine arabinoside (NSC 63878) therapy for acute leukemia in adults. Cancer Chemother Rep 1969; 53: 59–66
- Clarkson B., Dowling M. D., Gee T. S., et al. Treatment of acute leukemia in adults. Cancer 1975; 36: 775–795
- Capizzi R. L., Poole M., Cooper M. R., et al. Treatment of poor risk acute leukemia with sequential high dose ara-C and asparaginase. Blood 1984; 63: 694–700
- Kessel D., Hall T. C., Rosenthal D. Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro. Cancer Res 1969; 29: 459–463
- Schrecker A. W., Urshel M. J. Metabolism of 1-β-D-arabinofuranosyl-cytosine in leukemia L1210: Studies with intact cells. Cancer Res 1968; 28: 793–801
- Plunkett W., Hug V., Keating M. J., et al. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 1980; 40: 588–591
- Meyers M. B., Kreis W. Comparison of enzymatic activities of two deoxycytidine kinases purified from cells sensitive (P815) or resistant (815/ara-C) to l-β-D-arabinofuranosylcytosine. Cancer Res 1978; 38: 1105–1112
- Furth J. J., Cohen S. S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5′ triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res 1968; 28: 2061–2067
- Graham F. L., Whitmore G. F. Studies in mouse L-cells on the incorporation of l-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by I-β-D-arabinofuranosylcytosine 5″-triphosphate. Cancer Res 1970; 30: 2636–2644
- Capizzi R. L., Yang J. L., Cheng E., et al. Alteration in the pharmacokinetics of high dose ara-C by its metabolite, high ara-U. in patients with acute leukemia. J Clin Oncol 1983; 1: 763–771
- Yang J. L., Cheng E. H., Capizzi R. L., et al. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia. J Clin Invest 1985; 75: 141–146
- Ho D. H. W., Carter C. J., Loo T. L. Effects of tetrahydrouridine (THU) on the uptake and metabolism of arabinosylcytosine by human acute myelogenous leukemia (AML) cells (abstr). Proc Am Assoc Cancer Res 1975; 16: 57
- Ahluwalia G. S., Cohen M. B., Kang G-J., et al. Arabinosyl-5-azacytidine: Mechanisms of native and acquired resistance. Cancer Res 1986; 46: 4479–4485
- Coleman C. N., Stoller R. G., Drake J. C., et al. Deoxycytidine kinase; properties of the enzyme from human leukemic granulocytes. Blood 1975; 46: 791–803
- Plunkett W., Liliemark J. O. Evidence that accumulation of ara-CTP by Leukemic cells is saturated during high-dose ara-C infusion: suggestions for increased efficiency of drug administration (abstr). Proc Am Soc Clin Oncol 1985; 4: 50
- Liliemark J. O., Plunkett W., Dixon D. O. Relationship of 1-β-D-Arabinofuransylcytosine in plasma to 1-β-D-arabinofuranosylcyto-sine 5′-triphosphate levels in leukemic cells during treatment with high dose l-β-D-anabinofuransylcytosine. Cancer Res 1985; 45: 5952–5957
- VanProoijen H. C., Dekker A. W., Punt K. The use of intermediate dose cytosine arabinoside (ID ara-C) in the treatment of acute non-lymphocytic leukemia in relapse. Br J Haematol 1984; 57: 291–299